The net profit in the third quarter was over seven billion euros.
(Photo: dpa)
Dusseldorf Investors on both sides of the Atlantic are pleased to see the new figures from pharmaceutical company Biontech for the third quarter. The share rose at times on the Xetra trading platform by more than ten percent to up to EUR 226. But then profit-taking set in – in the afternoon the price increase was gone.
A similar picture emerged in the USA: There, too, the paper listed on the Nasdaq technology exchange was five percent higher in pre-market US trading, after an increase of twelve percent the previous day. When trading began, however, the tide turned: The stock was 2.5 percent lower at $ 236.
Biontech achieved a net profit of 7.1 billion euros in the first nine months of the year. Sales rose to 13.4 billion euros – an increase of a factor of 100 compared to the same period in the previous year. In relation to the year as a whole, net profit should be more than nine billion euros.
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further